<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00010101</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000068445</org_study_id>
    <secondary_id>PBTC-N03</secondary_id>
    <nct_id>NCT00010101</nct_id>
  </id_info>
  <brief_title>Genetic Study of Brain Tumors in Young Children</brief_title>
  <official_title>INI1 Mutation Analysis and Expression Profiling of Embryonal CNS Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pediatric Brain Tumor Consortium</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Pediatric Brain Tumor Consortium</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Genetic studies may help in understanding the genetic processes involved in the&#xD;
      development of some types of cancer.&#xD;
&#xD;
      PURPOSE: Genetic study to understand how genes may be involved in the development of brain&#xD;
      tumors in young children.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the frequency and type of deletions and mutations of the INI1 gene in infants&#xD;
           with embryonal central nervous system tumors.&#xD;
&#xD;
        -  Compare the gene expression profiles in infants with atypical teratoid/rhabdoid tumors&#xD;
           vs medulloblastoma or primitive neuroectodermal tumor.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Tumor samples are analyzed by fluorescence in situ hybridization (FISH) for deletions of INI1&#xD;
      gene in chromosome band 22q11.2. Tumors without demonstration of deletions of INI1 gene by&#xD;
      FISH are examined by polymerase chain reaction (PCR)-based microsatellite analysis for loss&#xD;
      of heterozygosity using markers that map to 22q11.2.&#xD;
&#xD;
      DNA from tumor tissue is analyzed for mutations in the exons of the INI1 gene. Isolated&#xD;
      matched normal DNA may be analyzed for identification of germline mutations. Parental DNA may&#xD;
      be analyzed to identify inherited germline mutations of the INI1 gene.&#xD;
&#xD;
      The patient's physician may receive the results of the genetic testing. The results do not&#xD;
      influence the type or duration of treatment.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 50 patients will be accrued for this study within 25 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Poor accrual&#xD;
  </why_stopped>
  <start_date>March 2001</start_date>
  <completion_date type="Actual">August 2004</completion_date>
  <primary_completion_date type="Actual">August 2004</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Deletions and mutations of the INI1 gene in infants with AT/RT, medulloblastoma, PNET, or choroid plexus carcinoma</measure>
  </primary_outcome>
  <enrollment type="Actual">38</enrollment>
  <condition>Central Nervous System Tumor, Pediatric</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Tumor samples&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Tissue samples from infants (&lt; 3 years old) with histologically confirmed primary&#xD;
        intracranial CNS medulloblastoma/PNET, atypical teratoid/rhabdoid tumor, or choroid plexus&#xD;
        carcinoma and with no prior chemotherapy, radiotherapy, or treatment from any other&#xD;
        investigational agent will be used for this research study. Patients who meet the&#xD;
        eligibility criteria, are treated at a PBTC institution that has IRB approval of this&#xD;
        study, and consent to the usage of stored tumor specimens for the study objectives&#xD;
        constitute the study population.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed primary intracranial central nervous system tumor&#xD;
&#xD;
               -  Medulloblastoma&#xD;
&#xD;
               -  Primitive neuroectodermal tumor&#xD;
&#xD;
               -  Atypical teratoid/rhabdoid tumor&#xD;
&#xD;
               -  Choroid plexus carcinoma&#xD;
&#xD;
          -  Potential enrollment on PBTC-001 therapeutic protocol&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  Under 3&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  No prior chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Prior steroids allowed&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  No prior radiotherapy&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No concurrent investigational agents&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>3 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jaclyn A. Biegel, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Children's Hospital of Philadelphia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's National Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010-2970</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104-4318</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Children's Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-2399</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Pomeroy SL, Tamayo P, Gaasenbeek M, Sturla LM, Angelo M, McLaughlin ME, Kim JY, Goumnerova LC, Black PM, Lau C, Allen JC, Zagzag D, Olson JM, Curran T, Wetmore C, Biegel JA, Poggio T, Mukherjee S, Rifkin R, Califano A, Stolovitzky G, Louis DN, Mesirov JP, Lander ES, Golub TR. Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature. 2002 Jan 24;415(6870):436-42.</citation>
    <PMID>11807556</PMID>
  </results_reference>
  <verification_date>July 2011</verification_date>
  <study_first_submitted>February 2, 2001</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>July 19, 2011</last_update_submitted>
  <last_update_submitted_qc>July 19, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 20, 2011</last_update_posted>
  <responsible_party>
    <name_title>James M. Boyett/PBTC Operations and Biostatistics Center Executive Director</name_title>
    <organization>Pediatric Brain Tumor Consortium</organization>
  </responsible_party>
  <keyword>childhood choroid plexus tumor</keyword>
  <keyword>untreated childhood supratentorial primitive neuroectodermal tumor</keyword>
  <keyword>untreated childhood medulloblastoma</keyword>
  <keyword>childhood atypical teratoid/rhabdoid tumor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

